Business
Omada Health’s GLP-1 Behavior Change Companion Programs Help Drive Lasting, Long-Term Weight Loss
New analysis adds to existing evidence that Omada’s program paired with GLP-1 medications leads to greater weight loss and persistence than reported in real
About this update from Omada Health, Inc.
[{"type":"text","content":"New analysis adds to existing evidence that Omada’s program paired with GLP-1 medications leads to greater weight loss and persistence than reported in real world evidence\nSAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit health care provider, today announced results from a 12-month real-world analysis of members in its GLP-1 companion program. By extending a previous six-month analysis, findings underscore the program’s role in helping employers manage the complexity of today’s weight loss medication market while delivering measurable, long-term value.1 The new analysis found that members who stayed in the program and persisted on their medication for 12 months had an average weight loss of 18.4% at one year,1 compared to 11.9% weight loss seen in real world evidence.2 Among those who persisted, Omada members achieved 47% greater average weight loss on semaglutide and 37% greater weight loss on tirzepatide,1 compared to published real world evidence.2 Moreover, the analysis showed an increase in weight loss across all members in the program, including those who did and did not persist with GLP-1s for the entire year, with an average 16.3% weight loss1 – nearly twice the amount observed in the real world analysis.2 “The promise of GLP-1s is clear: significant weight loss that unlocks broader health benefits. But that promise requires persistence through real-world challenges. As the GLP-1 landscape evolves with new access models and pricing strategies, employers need confidence that wraparound support delivers lasting value,” said Wei-Li Shao, President at Omada Health. \"These outcomes demonstrate that with the right support, members can achieve the weight loss they need to improve their health. That's how behavioral support transforms medication coverage from a cost into an investment.” The analysis followed 965 Omada members without diabetes who self-reported GLP-1 use and participated in Omada Health’s Enhanced GLP-1 Care Track, which provides resources for medication support and lifestyle change. Pharmacy claims and clinical data from a 12-month period were used to evaluate medication persistence and health outcomes among these members, all of whom had recently begun GLP-1 therapy for weight loss at program start. For people on GLP-1s, medication persistence is k...